{"id":"W2785021126","doi":"10.1182/blood.v130.suppl_1.650.650","title":"Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Brentuximab vedotin; Oncology; Refractory (planetary science); Phases of clinical research; Clinical trial; Lymphoma; Cancer; Hodgkin lymphoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001344871,0.0003635001,0.0005455664,0.0002152792,0.0002455635,0.0007658711,0.0004660544,0.0004933517,0.0008120214],"category_scores_gemma":[0.001037179,0.0001613089,0.0009513542,0.0002818768,0.0002549799,0.0004576587,0.0004581725,0.0008482977,0.0001583284],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006723211,"about_ca_system_score_gemma":0.0005238439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001057117,"about_ca_topic_score_gemma":0.002430625,"domain_scores_codex":[0.9996797,0.0001466667,0.00002417919,0.00006296012,0.00004231706,0.00004425605],"domain_scores_gemma":[0.9992361,0.0001174559,0.0002337541,0.00006825267,0.00007432776,0.0002701758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.258318,0.005656962,0.6269138,0.001324099,0.006213367,0.0004460141,0.0004452733,0.002648165,0.01061668,0.0004071393,0.009686024,0.07732439],"study_design_scores_gemma":[0.04791234,0.05618158,0.8815743,0.0002471632,0.003769896,0.0006827262,0.000215669,0.002201562,0.001633929,0.0003329997,0.005184284,0.0000636],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960871,0.001695918,0.00007417476,0.0001311453,0.00002459626,0.0001365802,0.001209009,0.000008144185,0.0006333983],"genre_scores_gemma":[0.9954905,0.0004447495,0.0001544577,0.0003204331,0.00007081793,0.0001489286,0.003110716,0.000003607647,0.0002558486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001344871,"threshold_uncertainty_score":0.007112443,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02050662511819855,"score_gpt":0.3048106614559048,"score_spread":0.2843040363377062,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}